Cargando…
Platelet Reactivity and Coagulation Markers in Patients with COVID-19
INTRODUTION: COVID-19 is associated with an increased risk of thrombotic events. However, the contribution of platelet reactivity (PR) to the aetiology of the increased thrombotic risk associated with COVID-19 remains unclear. Our aim was to evaluate PR in stable patients diagnosed with COVID-19 and...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176448/ https://www.ncbi.nlm.nih.gov/pubmed/34086266 http://dx.doi.org/10.1007/s12325-021-01803-w |
_version_ | 1783703261791911936 |
---|---|
author | Bertolin, Adriadne J. Dalçóquio, Talia F. Salsoso, Rocío de M. Furtado, Remo H. Kalil-Filho, Roberto Hajjar, Ludhmila A. Siciliano, Rinaldo F. Kallás, Esper G. Baracioli, Luciano M. Lima, Felipe G. Giraldez, Roberto R. Cavalheiro-Filho, Cyrillo Vieira, Alexandra Strunz, Célia M. C. Giugliano, Robert P. Tantry, Udaya S. Gurbel, Paul A. Nicolau, José C. |
author_facet | Bertolin, Adriadne J. Dalçóquio, Talia F. Salsoso, Rocío de M. Furtado, Remo H. Kalil-Filho, Roberto Hajjar, Ludhmila A. Siciliano, Rinaldo F. Kallás, Esper G. Baracioli, Luciano M. Lima, Felipe G. Giraldez, Roberto R. Cavalheiro-Filho, Cyrillo Vieira, Alexandra Strunz, Célia M. C. Giugliano, Robert P. Tantry, Udaya S. Gurbel, Paul A. Nicolau, José C. |
author_sort | Bertolin, Adriadne J. |
collection | PubMed |
description | INTRODUTION: COVID-19 is associated with an increased risk of thrombotic events. However, the contribution of platelet reactivity (PR) to the aetiology of the increased thrombotic risk associated with COVID-19 remains unclear. Our aim was to evaluate PR in stable patients diagnosed with COVID-19 and hospitalized with respiratory symptoms (mainly dyspnoea and dry cough), in comparison with a control group comprised of non-hospitalized healthy controls. METHODS: Observational, case control study that included patients with confirmed COVID-19 (COVID-19 group, n = 60) and healthy individuals matched by age and sex (control group, n = 60). Multiplate electrode aggregometry (MEA) tests were used to assess PR with adenosine diphosphate (MEA-ADP, low PR defined as < 53 AUC), arachidonic acid (MEA-ASPI, low PR < 86 AUC) and thrombin receptor-activating peptide 6 (MEA-TRAP, low PR < 97 AUC) in both groups. RESULTS: The rates of low PR with MEA-ADP were 27.5% in the COVID-19 group and 21.7% in the control group (OR = 1.60, p = 0.20); with MEA-ASPI, the rates were, respectively, 37.5% and 22.5% (OR = 3.67, p < 0.001); and with MEA-TRAP, the incidences were 48.5% and 18.8%, respectively (OR = 9.58, p < 0.001). Levels of d-dimer, fibrinogen, and plasminogen activator inhibitor 1 (PAI-1) were higher in the COVID-19 group in comparison with the control group (all p < 0.05). Thromboelastometry was utilized in a subgroup of patients and showed a hypercoagulable state in the COVID-19 group. CONCLUSION: Patients hospitalized with non-severe COVID-19 had lower PR compared to healthy controls, despite having higher levels of d-dimer, fibrinogen, and PAI-1, and hypercoagulability by thromboelastometry. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT04447131. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01803-w. |
format | Online Article Text |
id | pubmed-8176448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-81764482021-06-04 Platelet Reactivity and Coagulation Markers in Patients with COVID-19 Bertolin, Adriadne J. Dalçóquio, Talia F. Salsoso, Rocío de M. Furtado, Remo H. Kalil-Filho, Roberto Hajjar, Ludhmila A. Siciliano, Rinaldo F. Kallás, Esper G. Baracioli, Luciano M. Lima, Felipe G. Giraldez, Roberto R. Cavalheiro-Filho, Cyrillo Vieira, Alexandra Strunz, Célia M. C. Giugliano, Robert P. Tantry, Udaya S. Gurbel, Paul A. Nicolau, José C. Adv Ther Original Research INTRODUTION: COVID-19 is associated with an increased risk of thrombotic events. However, the contribution of platelet reactivity (PR) to the aetiology of the increased thrombotic risk associated with COVID-19 remains unclear. Our aim was to evaluate PR in stable patients diagnosed with COVID-19 and hospitalized with respiratory symptoms (mainly dyspnoea and dry cough), in comparison with a control group comprised of non-hospitalized healthy controls. METHODS: Observational, case control study that included patients with confirmed COVID-19 (COVID-19 group, n = 60) and healthy individuals matched by age and sex (control group, n = 60). Multiplate electrode aggregometry (MEA) tests were used to assess PR with adenosine diphosphate (MEA-ADP, low PR defined as < 53 AUC), arachidonic acid (MEA-ASPI, low PR < 86 AUC) and thrombin receptor-activating peptide 6 (MEA-TRAP, low PR < 97 AUC) in both groups. RESULTS: The rates of low PR with MEA-ADP were 27.5% in the COVID-19 group and 21.7% in the control group (OR = 1.60, p = 0.20); with MEA-ASPI, the rates were, respectively, 37.5% and 22.5% (OR = 3.67, p < 0.001); and with MEA-TRAP, the incidences were 48.5% and 18.8%, respectively (OR = 9.58, p < 0.001). Levels of d-dimer, fibrinogen, and plasminogen activator inhibitor 1 (PAI-1) were higher in the COVID-19 group in comparison with the control group (all p < 0.05). Thromboelastometry was utilized in a subgroup of patients and showed a hypercoagulable state in the COVID-19 group. CONCLUSION: Patients hospitalized with non-severe COVID-19 had lower PR compared to healthy controls, despite having higher levels of d-dimer, fibrinogen, and PAI-1, and hypercoagulability by thromboelastometry. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT04447131. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01803-w. Springer Healthcare 2021-06-04 2021 /pmc/articles/PMC8176448/ /pubmed/34086266 http://dx.doi.org/10.1007/s12325-021-01803-w Text en © The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Research Bertolin, Adriadne J. Dalçóquio, Talia F. Salsoso, Rocío de M. Furtado, Remo H. Kalil-Filho, Roberto Hajjar, Ludhmila A. Siciliano, Rinaldo F. Kallás, Esper G. Baracioli, Luciano M. Lima, Felipe G. Giraldez, Roberto R. Cavalheiro-Filho, Cyrillo Vieira, Alexandra Strunz, Célia M. C. Giugliano, Robert P. Tantry, Udaya S. Gurbel, Paul A. Nicolau, José C. Platelet Reactivity and Coagulation Markers in Patients with COVID-19 |
title | Platelet Reactivity and Coagulation Markers in Patients with COVID-19 |
title_full | Platelet Reactivity and Coagulation Markers in Patients with COVID-19 |
title_fullStr | Platelet Reactivity and Coagulation Markers in Patients with COVID-19 |
title_full_unstemmed | Platelet Reactivity and Coagulation Markers in Patients with COVID-19 |
title_short | Platelet Reactivity and Coagulation Markers in Patients with COVID-19 |
title_sort | platelet reactivity and coagulation markers in patients with covid-19 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176448/ https://www.ncbi.nlm.nih.gov/pubmed/34086266 http://dx.doi.org/10.1007/s12325-021-01803-w |
work_keys_str_mv | AT bertolinadriadnej plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT dalcoquiotaliaf plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT salsosorocio plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT demfurtadoremoh plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT kalilfilhoroberto plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT hajjarludhmilaa plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT sicilianorinaldof plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT kallasesperg plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT baraciolilucianom plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT limafelipeg plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT giraldezrobertor plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT cavalheirofilhocyrillo plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT vieiraalexandra plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT strunzceliamc plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT giuglianorobertp plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT tantryudayas plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT gurbelpaula plateletreactivityandcoagulationmarkersinpatientswithcovid19 AT nicolaujosec plateletreactivityandcoagulationmarkersinpatientswithcovid19 |